Previous 10 | Next 10 |
DR. MORRIS C. LASTER WINS PROXY CONTEST AS STOCKHOLDERS ELECT HIS NOMINEES TO SCOPUS BIOPHARMA INC. BOARD OF DIRECTORS Former CEO/Director Dr. Morris C. Laster Believes Election of New Directors to Scopus's Board Will Help Ensure Effective, Independent Oversight of Company's Aff...
Latest Legal Claims by Laster Actually Call into Question his Stock Ownership Company Urges Stockholders to Vote “FOR ALL” of the Company’s Director Nominees on the WHITE Proxy Card NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. ...
Energy Focus (NASDAQ:EFOI) +52% launches nUVo virus-targeted UVC air disinfectors to public. Lexaria Bioscience (NASDAQ:LEXX) +25% dehydraTECHTM-CBD reduces arterial stiffness, results confirmed in human clinical study HYPER-H21-2. Dare Bioscience (NASDAQ:DARE) +23% announces F...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! We’ve reached the halfway point of the week and there’s no slowing down as we dive into the biggest pre-market stock movers for Wednesday! Source: f11photo/Shutterstock.com We...
Company’s Director Nominees are Highly Qualified and Experienced with Track Records of Guiding Early-Stage Life Science Companies Executing Strategy to Create an Industry-Leading Portfolio of Bi-Functional Cancer Targeting Molecules Recently Raised $9.75 Million i...
Dr. Morris C. Laster Issues An Open Letter To Scopus BioPharma Inc. Stockholders In Connection With Upcoming Annual Meeting Former CEO/Director Dr. Morris C. Laster Believes Immediate Change is Required to Scopus's Board to Ensure Effective, Independent Oversight of Company's Af...
NEW YORK, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) , a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced it has entered into se...
NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) , a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced that, on October 8, 20...
Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology Presentation to include a discussion of preclinical data released at the 17 th Annual Meeting of the Oligonucleotide Therapeutics Society ...
RALEIGH, NC / ACCESSWIRE / October 4, 2021 / The Fall Harvest - Best Ideas from the Buy-Side will take place on October 5 th - 8 th , 2021, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience. The Fall Harvest - Best...
News, Short Squeeze, Breakout and More Instantly...
Scopus BioPharma Inc. Company Name:
SCPS Stock Symbol:
NASDAQ Market:
Scopus BioPharma Inc. Website:
DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma Data Suggests Benefits of Combinations of DUET-102 with Other T-Cell Based Immunotherapies, such as CAR-Ts NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Scopus B...
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS ”) , a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical need, and its subsidiary, Duet BioTherapeutics Inc., which is...
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) , a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, and its pure-play immuno-oncology subsidiary, Duet Bi...